Physician profile
Sheldon Oberfeld
NPI 1134158306
$988.45
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $34.80 · 2021: $176 · 2022: $237 · 2023: $182 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $236.22 | 2019-2023 | |
| Oyster Point Pharma, INC. | $123.47 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $103.21 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $83.35 | 2022-2024 | Lotemax Sm, Vyzulta, Prolensa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.15 | 2019-2021 | |
| Abbvie INC. | $69.93 | 2022-2023 | |
| Eyevance Pharmaceuticals LLC | $63.86 | 2019 | |
| Alcon Vision LLC | $45.02 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $34.23 | 2019 | |
| Dompe US, INC. | $27.95 | 2024 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $23.30 | 2023 | Quatera 700 |
| Tarsus Pharmaceuticals, INC. | $19.21 | 2024 | Xdemvy |
| Amgen INC. | $15.89 | 2024 | Tepezza |
| Genmab U.S., INC. | $14.64 | 2022 | |
| Horizon Therapeutics Plc | $14.42 | 2023 | Tepezza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $14.13 | 2021 | |
| Shire North American Group INC | $12.37 | 2019 | |
| Sun Pharmaceutical Industries INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Oberfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.